Ładuje się......
Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study
OBJECTIVE: Ocrelizumab (OCR) is a monoclonal antibody directed at B-cells that is FDA approved for treatment of RRMS and PPMS. Prior studies have raised concerns about patients’ ability to form antibodies in response to various antigens, especially SARS-CoV-2. The objective of this study is to deter...
Zapisane w:
| Wydane w: | Mult Scler Relat Disord |
|---|---|
| 1. autor: | |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Elsevier B.V.
2021
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8102087/ https://ncbi.nlm.nih.gov/pubmed/34000684 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2021.103014 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|